The End of Territory-Based Selling: How Behavioral Analytics Is Redefining HCP Engagement

Let us begin with an honest acknowledgment: the geographic sales territory was never really a sales strategy. It was a logistics solution — a practical method for distributing a fixed number of field representatives across a fixed geographic landscape in the days when the primary information asymmetry was geographic. The doctor in rural Ohio simply hadn't heard about the drug that physicians in Cleveland were prescribing. Putting a rep in the car to drive between them was the most efficient mechanism for closing that information gap.

That asymmetry no longer exists. In an era of medical journals searchable in seconds, real-time prescribing data, peer networks that span continents, digital medical education, and 24-hour access to clinical content of every conceivable kind, the information gap that justified territory-based selling has been almost entirely eliminated. What remains is a commercial infrastructure — territorial assignments, target lists built on geography and crude prescription volume, quarterly call cycles, and field force metrics calibrated to activity rather than impact — that was architected for a world that no longer exists.

The consequences are measurable and severe. A 2023 EPG Health report found that two-thirds of healthcare providers want to interact with sales representatives no more than once per month, and nearly 70% believe representatives fail to understand their content needs. A 2025 analysis published by PharmExec found that physicians still find only one-third of sales calls valuable, that more than 20% of physicians actively restrict representative access, and that nearly 90% of field interactions last fewer than two minutes. Top pharmaceutical companies spend between $4 million and $6 million annually on third-party sales force effectiveness research — and many commercial executives privately acknowledge that the insights rarely move the business.

This is not a field force failure. It is a model failure. And the pharmaceutical industry is finally, comprehensively, beginning to build what replaces it.

Three forces converged between 2020 and 2023 to make the transition from territory-based to behavioral-analytics-driven commercial models not just possible but necessary.

The first was the pandemic-accelerated collapse of the in-person call as the default engagement channel. When field forces were grounded in early 2020, pharmaceutical companies were forced to build digital engagement infrastructure at emergency speed. Many discovered, to their surprise, that certain HCP segments were more reachable, more receptive, and more efficiently engaged through digital channels than through field visits. The question that emerged from that discovery was not whether digital channels work — it was how to know which channels work for which physicians, when, and with what content. That question is a data question. It is a behavioral analytics question.

The second was the explosion of available HCP behavioral data. The combination of real-time prescription data, healthcare provider digital activity data, medical claims, specialty society engagement records, continuing medical education completion data, peer publication patterns, formulary decision participation, and first-party digital engagement signals from owned web properties created, for the first time, a genuinely comprehensive behavioral signal about individual healthcare providers. Indegene's 2024 HCP Digital Affinity Report, which followed 2.1 million U.S. clinicians, found that channel preferences can shift by double digits within a single quarter — and that among physicians under 30, only 33% qualify as consistent digital enthusiasts or regulars, while the remainder drift between face-to-face and digital touchpoints. Annual target list refreshes, calibrated to geography and last year's prescribing volume, are structurally incapable of responding to that kind of behavioral churn.

The third was the maturation of the analytical infrastructure needed to turn that behavioral signal into commercial action. Next-best-action engines, dynamic segmentation platforms, behavioral signal graphs, and AI-powered personalization systems have reached the scale, accuracy, and usability levels required for field-force integration. Axtria's 2025 Customer Engagement Planning and Execution Benchmarking Study found that adoption of dynamic targeting by large pharmaceutical companies rose from 17% in 2023 to 25% in 2024 — a meaningful acceleration driven by the demonstrated performance advantage of real-time behavioral targeting over quarterly static target lists.

The industry has crossed an inflection point. The leading companies are not experimenting with behavioral analytics. They are rebuilding their commercial architectures around it.

Before we examine what leading companies are building, it is worth being precise about what behavioral analytics in the context of HCP engagement actually means — because the term is used loosely, and the looseness creates commercial risk.

Behavioral analytics, properly defined, is the use of observed HCP behavior across multiple data sources and channels to understand, predict, and respond to individual physician preferences, decision states, and engagement propensities. It is fundamentally distinct from three things it is commonly confused with:

What behavioral analytics does is construct a dynamic, continuously updated model of each HCP's engagement state: their clinical focus areas and how they are evolving, their channel preferences and how they vary by time of day and week, their content consumption patterns and what they reveal about scientific interests and prescribing decision processes, their peer network position and the influence dynamics within their referral and consultation network, and their engagement trajectory — whether they are moving toward greater interest in a therapeutic area or away from it.

This model, applied at scale, produces something that geography never could: a ranked, continuously refreshed, actionable view of which physicians to engage, through what channel, with what content, at what moment, and to what end.

What are leading pharmaceutical companies actually building? Based on commercial analytics implementations across the industry, a clear architecture has emerged.

The question that generates the most anxiety in commercial organizations when this architecture is described is a predictable one: what happens to field sales representatives?

The honest answer is that their role changes significantly — and in most cases, becomes more valuable, not less.

The representative who visits 20 physicians per day in a predetermined geographic circuit, delivering the same detail aid to physicians with vastly different levels of product awareness, clinical focus, and engagement history, is adding limited commercial value. That role is already being rationalized in every forward-looking commercial organization, with good reason.

The representative who operates as an orchestrator of personalized, data-informed physician engagement — who knows, before entering a physician's office, exactly where that physician is in their clinical journey with the relevant therapeutic area, what content they have consumed, what questions their behavioral signal suggests they are working through, what peer influences are most active in their decision-making network, and what specific commercial intervention is most likely to advance the relationship — that representative is adding enormous value that no digital channel can replicate.

The data on behavioral analytics-driven commercial model performance is now sufficiently robust to move beyond case study anecdotes.

Multiple analyses published between 2023 and 2025 converge on a consistent finding: pharmaceutical brands that have implemented dynamic behavioral targeting in their commercial models outperform those operating on static territory-based models across the metrics that matter most to commercial leaders.

Targeting precision improves substantially — the Alpha Sophia data showing a 15-point lift in the share of interactions reaching genuinely high-propensity HCPs is consistent with the directional findings from other analyses. Cost per incremental prescription improves by 25–35% in mature implementations. HCP satisfaction with pharmaceutical commercial engagement, measured by third-party physician surveys, improves significantly when behavioral analytics-informed engagement replaces frequency-based territory coverage.

The pharmaceutical commercial model is in the middle of a transformation that will take the better part of this decade to complete. The companies at the leading edge are not waiting to see how it plays out. They are making the investments now that will define their commercial performance in the next product generation.

By 2026, dynamic behavioral targeting has moved from a differentiator to an emerging baseline expectation among top-tier pharmaceutical companies. The next competitive frontier is moving further up the behavioral analytics maturity curve: from knowing who to engage and when, to predicting what specific clinical reasoning pathways individual physicians will follow when making complex prescribing decisions, and designing commercial interventions that engage with those pathways at the cognitive level where decisions are actually made.

The geographic territory was never a strategy. The question is no longer whether to replace it.

The question is how quickly — and how well.